Head to Head Analysis: Orchestra BioMed (OBIO) and Its Rivals

Orchestra BioMed (NASDAQ:OBIO) is one of 229 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare Orchestra BioMed to similar companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for Orchestra BioMed and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	2	0	3.00
Orchestra BioMed Competitors	1557	4232	8384	216	2.50

Orchestra BioMed presently has a consensus target price of $17.00, suggesting a potential upside of 222.58%. As a group, “Surgical & medical instruments” companies have a potential upside of 21.69%. Given Orchestra BioMed’s stronger consensus rating and higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than its peers.

Institutional & Insider Ownership

53.6% of Orchestra BioMed shares are held by institutional investors. Comparatively, 48.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.1% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Orchestra BioMed has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Orchestra BioMed’s peers have a beta of 1.13, meaning that their average stock price is 13% more volatile than the S&P 500.

Earnings and Valuation

This table compares Orchestra BioMed and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	-$2.73 million	-3.51
Orchestra BioMed Competitors	$1.05 billion	$4.10 million	-9.70

Orchestra BioMed’s peers have higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Orchestra BioMed and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-1,779.71%	-54.81%	-38.93%
Orchestra BioMed Competitors	-649.87%	-420.10%	-31.28%

Summary

Orchestra BioMed peers beat Orchestra BioMed on 7 of the 13 factors compared.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in patients indicated for a cardiac pacemaker; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.